Table 1 Synthetic Lethal Interactions Identified in Lung Cancer
From: Synthetic lethality in lung cancer and translation to clinical therapies
Interactor 1 | Interactor 2 | Type of Interaction | Method of Discovery | Lung Cancer Subtype | Year discovered | First Author | PMID |
|---|---|---|---|---|---|---|---|
PAPSS1 | Cisplatin (or other DNA damaging agents) | Chemo-sensitization | RNAi Screen (siRNA) + Low-Dose Cisplatin | LAC | 2015 | Leung | 26220590 |
CABYR | Cisplatin | Chemo-sensitization | RNAi Screen (siRNA) + Cisplatin | LAC | 2014 | Qian Leung | 24362251 26938915 |
dUTPase | FUdR/pemetrexed | Chemo-sensitization | Hypothesis Based | LAC; bronchioalveolar carcinoma; LCC | 2012 | Wilson | 22172489 |
mKRAS | PKCi Aggegation (via Oncrasin-1 treatment) | GOF + GOF | Chemical library Compound Screen | LAC | 2008 | Guo | 18794128 |
mKRAS | mEGFR | GOF + GOF | Computational - Mutual Exclusivity Analysis in Lung Cancer Genomic Data | LAC | 2015 | Unni/Lockwood | 26047463 |
mKRAS | mBRAF | GOF + GOF | Hypothesis Based | LAC | 2016 | Cisowski | 26028035 |
mEGFR | ARHG5 | GOF + LOF | Computational - EGFR Interactome Mapping | LAC | 2013 | Li | 24189400 |
mKRAS | GATA2 | GOF + LOF | RNAi Screen (siRNA) | LAC | 2012 | Kumar | 22541434 |
mKRAS | STK33 | GOF + LOF | RNAi Screen (shRNA) | LAC | 2009 | Scholl | 19490892 |
mKRAS | TBK1 | GOF + LOF | RNAi Screen (shRNA) | LAC | 2009 | Barbie | 19847166 |
mKRAS | PLK1 | GOF + LOF | RNAi Screen (shRNA) | LAC | 2009 | Luo | 19490893 |
mKRAS | WT1 | GOF + LOF | RNAi Screen (shRNA) | LAC | 2010 | Vicent | 20972333 |
mKRAS | CDK4 | GOF + LOF | RNAi Screen (shRNA) | LAC | 2010 | Puyol | 20609353 |
MYC | PRKDC | GOF + LOF | RNAi Screen (shRNA) | SCLC | 2014 | Zhou | 25495526 |
mEGFR | PRKCSH + EGFR-i | GOF + LOF + LOF | RNAi Screen (shRNA) + Gefitinib | LAC | 2014 | Sudo | 25528770 |
mEGFR | NF-kB + EGFR-i | GOF + LOF + LOF | RNAi Screen (shRNA/siRNA) + EGFR TKI | LAC | 2011;2015 | Bivona Blakely | 21430781 25843712 |
mKRAS | BCL-XL + MEK-i | GOF + LOF + LOF | RNAi Screen (shRNA) + Selumetinib | LAC | 2013 | Corcoran | 23245996 |
ATM | DNAPK | LOF + LOF | Hypothesis Based | LAC | 2013 | Riabinska | 23761041 |
ATM/p53 | ATR (under DNA damaging conditions) | LOF + LOF | Hypothesis Based | LAC | 2011 | Reaper | 21490603 |
EGFR | Tankyrase 1 | LOF + LOF | RNAi Screen (shRNA) + Gefitinib | LAC | 2012 | Casas-Selves | 22738915 |
MAX | BRG1 | LOF + LOF | Computational - Global gene expression analysis; cancer databases | SCLC | 2014 | Romero | 24362264 |
RB1 | CDKN2A | LOF + LOF | Computational - Proteome/transcriptome profiling | LAC; SCLC | 2016 | Kim | 26647789 |
LKB1 | phenformin | LOF + LOF | Compound library screen | LAC | 2013 | Shackelford | 23352126 |
BRM/SMARCA2 | BRG1 | LOF + LOF/collateral | RNAi Screen (shRNA) | LAC | 2014 | Hoffman Orvis Wilson Oike | 24520176 25115300 24421395 23872584 |
PSMA1 (proteosome subunit) | Radiation | Radio-sensitization | RNAi Screen (shRNA) | LAC; LCC | 2013 | Cron | 24040035 |
Cisplatin | Irinotecan | Synergistic Interaction | Hypothesis Based | SCLC | 2002 | Noda | 11784874 |